Human papillomavirus type 16 E2 protein transcriptionally activates the promoter of a key cellular splicing factor, SF2/ASF

Journal of Virology

Volumn 83, Issue 1, 2009, Pages 357-367

  Mole, Sarah ^a   Milligan, Steven G ^a   Graham, Sheila V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; VIRUS PROTEIN; DNA BINDING PROTEIN; E2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; NUCLEAR PROTEIN; ONCOPROTEIN; SFRS1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CLONE; DNA BINDING; DNA SPLICING; EPITHELIUM CELL; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; LIFE CYCLE; PRIORITY JOURNAL; RNA PROCESSING; TRANSCRIPTION INITIATION; BIOSYNTHESIS; CELL LINE; METABOLISM; PHYSIOLOGY; PROTEIN BINDING;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE;

CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMAN PAPILLOMAVIRUS 16; HUMANS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, VIRAL; PROTEIN BINDING; TRANSCRIPTIONAL ACTIVATION;

EID: 58149378393     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01414-08     Document Type: Article

References (66)

1. Aasen, T., M. B. Hodgins, M. Edward, and S. V. Graham. 2003. The relationship between connexins, gap junctions, tissue architecture and tumour invasion, as studied in a novel in vitro model of HPV-16-associated cervical cancer progression. Oncogene 22:7969-7980.
2. Bedell, M. A., J. B. Hudson, T. R. Golub, M. E. Turyk, M. Hosken, G. D. Wilbanks, and L. A. Laimins. 1991. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J. Virol. 65:2254-2260.
3. Bell, S. D., and J. D. Barry. 1995. Trypanosome nuclear factors which bind to internal promoter elements of tRNA genes. Nucleic Acids Res. 23:3103-3110.
4. Benson, J. D., R. Lawande, and P. M. Howley. 1997. Conserved interaction of the papillomavirus E2 transcriptional activator proteins with human and yeast TFIIB proteins. J. Virol. 71:8041-8047.
5. Beyer-Finkler, E., M. H. Stoler, F. Girardi, and H. J. Pfister. 1990. Cell differentiation-related gene expression of human papillomavirus 33. Med. Microbiol. Immunol. 179:185-192.
6. Bouvard, V., A. Storey, D. Pim, and L. Banks. 1994. Characterization of the human papillomavirus E2 protein: evidence of trans-activation and transrepression in cervical keratinocytes. EMBO J. 13:5451-5459.
7. Cáceres, J. F., and A. R. Kornblihtt. 2002. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 18: 186-193.
8. Carrillo, E., E. Garrido, and P. Gariglio. 2004. Specific in vitro interaction between papillomavirus E2 proteins and TBP-associated factors. Intervirology 47:342-349.
9. CheunIm, T., J. Zhang, S. G. Milligan, M. G. McPhillips, and S. V. Graham. 2008. The alternative splicing factor hnRNP A1 is up-regulated during virus-infected epithelial cell differentiation and binds the human papillomavirus type 16 late regulatory element. Virus Res. 131:189-198.
10. Collier, B., L. Goobar, M. Sokolowski, and S. Schwartz. 1998. Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogeneous ribonucleoprotein K and poly(rC)-binding proteins 1 and 2. J. Biol. Chem. 273:22648-22656.
11. Collier, B., D. Oberg, X. Zhao, and S. Schwartz. 2002. Specific inactivation of inhibitory sequences in the 5′ end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J. Virol. 76:2739-2752.
12. Cumming, S. A., M. G. McPhillips, T. Veerapraditsin, S. G. Milligan, and S. V. Graham. 2003. Activity of the human papillomavirus type 16 late negative regulatory element is partly due to four weak consensus 5′ splice sites that bind a U1 snRNP-like complex. J. Virol. 77:5167-5177.
13. Dell, G., K. W. Wilkinson, R. Tranter, J. L. Parish, R. L. Brady, and K. Gaston. 2003. Comparison of the structure and DNA-binding properties of the E2 proteins from an oncogenic and non-oncogenic human papillomavirus. J. Mol. Biol. 334:979-991.
14. Enzenauer, C., G. Mengus, A. Lavigne, I. Davidson, H. J. Pfister, and M. May. 1998. Interaction of human papillomavirus 8 regulatory proteins E2, E6 and E7 with components of the TFIID complex. Intervirology 41:670-680.
15. Eperon, I. C., O. V. Makarova, A. Mayeda, S. H. Munroe, J. F. Caceres, D. G. Hayward, and A. R. Krainer. 2000. Selection of alternative 5′ splice sites: role of U1 snRNP and models for the antagonistic effects of SF2/ASF and hnRNP A1. Mol. Cell. Biol. 20:8303-8318.
16. Fuchs, E., and C. Byrne. 1994. The epidermis: rising to the surface. Curr. Opin. Gen. Dev. 4:725-736.
17. Fukuhara, T., T. Hosoya, S. Shimizu, K. Sumi, T. Oshiro, Y. Yoshinaka, M. Suzuki, N. Yamamoto, L. A. Herzenberg, L. A. Herzenberg, and M. Hagiwara. 2006. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc. Natl. Acad. Sci. USA 103:11329-11333.
18. Gomez-Roman, N., C. Grandori, R. N. Eisenman, and R. J. White. 2003. Direct activation of RNA polymerase III transcription by c-Myc. Nature 421:290-294.
19. Goraczniak, R., and S. I. Gunderson. 2008. The regulatory element in the 3′-untranslated region of human papillomavirus 16 inhibits expression by binding CUG-binding protein 1. J. Biol. Chem. 283:2286- 2296.
20. Graham, S. V. 2008. Papillomavirus 3′UTR elements. Front. Bioscience 13:5646-5663.
21. Hadaschik, D., K. Hinterkeuser, M. Oldak, H. J. Pfister, and S. Smola-Hess. 2003. The papillomavirus E2 protein binds to and synergizes with C/EBP factors involved in keratinocyte differentiation. J. Virol. 77:5253-5265.
22. Hegde, R. S. 2002. The papillomavirus E2 proteins. Annu. Rev. Biophys. Biomol. Struct. 31:343-360.
23. Hegde, R. S., and E. J. Androphy. 1998. Crystal structure of the E2 DNA-binding domain from human papillomavirus type 16: implications for its DNA binding-site selection mechanism. J. Mol. Biol. 284:1479-1489.
24. Hines, C. S., C. Meghoo, S. Shetty, M. Biburger, M. Brenowitz, and R. S. Hegde. 1998. DNA structure and flexibility in the sequence-specific binding of papillomavirus E2 proteins. J. Mol. Biol. 276:809-818.
25. Hoffmann, R., B. Hirt, V. Bechtold, P. Beard, and K. Raj. 2006. Different modes of papillomavirus DNA replication during maintenance. J. Virol. 80:4431-4439.
26. Huang, Y., T. A. Yario, and J. A. Steitz. 2004. A molecular link between SR protein dephosphorylation and mRNA export. Proc. Natl. Acad. Sci. USA 101:9666-9670.
27. Jeon, S., B. L. Allen-Hoffman, and P. F. Lambert. 1995. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69:2989-2997.
28. Karni, R., E. de Stanchina, S. W. Lowe, R. Sinha, D. Mu, and A. R. Krainer. 2007. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14:185-193.
29. Kennedy, I. M., J. K. Haddow, and J. B. Clements. 1991. A negative regulatory element in the human papillomavirus type 16 genome acts at the level of late mRNA stability. J. Virol. 65:2093-2097.
30. Koffa, M. D., S. V. Graham, Y. Takagaki, J. L. Manley, and J. B. Clements. 2000. The human papillomavirus type 16 negative regulatory element interacts with three proteins that act at different posttranscriptional levels. Proc. Natl. Acad. Sci. USA 97:4677-4682.
31. Kozak, M. 1991. An analysis of vertebrate mRNA sequences: intimations of translational control. J. Cell Biol. 15:887-903.
32. Lai, M.-C., B. H. Teh, and W.-Y. Tarn. 1999. A human papillomavirus E2 transcriptional activator. J. Biol. Chem. 274:11832- 11841.
33. Lee, D., S. G. Hwang, J. Kim, and J. Choe. 2002. Functional interaction between p/CAF and human papillomavirus E2 protein. J. Biol. Chem. 277:6483-6489.
34. Lee, D., H.-Z. Kim, K. W. Jeong, Y. S. Shim, I. Horikawa, J. C. Barrett, and J. Choe. 2002. Human papillomavirus E2 down-regulates the human telomerase reverse transcriptase promoter. J. Biol. Chem. 277:27748- 27756.
35. Lee, D., B. Lee, J. Kim, D. W. Kim, and J. Choe. 2000. cAMP response element-binding protein binds to human papillomavirus E2 protein and activates E2-dependent transcription. J. Biol. Chem. 275:7045-7051.
36. Lemaire, R., J. Prasad, T. Kashima, J. Gustafson, J. L. Manley, and R. Lafyatis. 2002. Stability of PKCI-1-related mRNA is controlled by the splicing factor ASF/SF2: a novel function for SR proteins. Genes Dev. 16:594-607.
37. Li, R., J. D. Knight, S. P. Jackson, R. Tjian, and M. R. Botchan. 1991. Direct interaction between Sp1 and the BPV enhancer E2 protein mediates synergistic activation of transcription. Cell 65:493-505.
38. Li, X., and J. L. Manley. 2005. Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell 122:365-378.
39. 2 cell cycle arrest and apoptosis, but inhibits internucleosomal DNA fragmentation. Genes Dev. 19:2705-2714.
40. Maitland, N. J., S. Conway, N. S. Wilkinson, J. Ramsdale, J. R. Morris, C. M. Sanders, J. E. Burns, P. L. Stern, and M. Wells. 1998. Expression patterns of the human papillomavirus type 16 transcription factor E2 in low-and high-grade cervical intraepithelial neoplasia. J. Pathol. 186:275-280.
41. McPhillips, M. G., T. Veerapraditsin, S. A. Cumming, D. Karali, S. G. Milligan, W. Boner, I. M. Morgan, and S. V. Graham. 2004. SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during epithelial differentiation. J. Virol. 78:10598-10605.
42. Milligan, S. G., T. Veerapraditsin, B. Ahamat, S. Mole, and S. V. Graham. 2007. Analysis of novel human papillomavirus type 16 late mRNAs in differentiated W12 cervical epithelial cells. Virology 360:172-181.
43. Molin, M., and G. Akusjärvi. 2000. Overexpression of essential splicing factor ASF/SF2 blocks the temporal shift in adenovirus pre-mRNA splicing and reduces virus progeny formation. J. Virol. 74:9002-9009.
44. Morgan, I. M., J. Grindlay, and M. S. Campo. 1998. Epithelial specific transcriptional regulation of the bovine papillomavirus 4 promoter by E2. J. Gen. Virol. 79:501-508.
45. Öberg, D., B. Collier, X. Zhao, and S. Schwartz. 2003. Mutational inactivation of two distinct negative RNA elements in the human papillomavirus type 16 L2 coding region induces production of high levels of L2 in human cells. J. Virol. 77:11674-11684.
46. Oldak, M., H. Smola, M. Aumailley, F. Rivero, H. J. Pfister, and S. Smola-Hess. 2004. The human papillomavirus type 8 E2 protein suppresses β4-integrin expression in primary human keratinocytes. J. Virol. 78:10738-10746.
47. Parish, J. L., A. Kowalczyk, H. T. Chen, G. E. S. R. Reoder, M. Buckle, and K. Gaston. 2006. E2 proteins from high- and low-risk human papillomavirus types differ in their ability to bind p53 and induce apoptotic cell death. J. Virol. 80:4580-4590.
48. Peh, W. L., K. Middleton, N. Christensen, P. Nicholls, K. Egawa, K. Sotlar, J. Brandsma, A. Percival, J. Lewis, W. J. Liu, and J. Doorbar. 2002. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J. Virol. 76:10411-10416.
49. Rank, N. M., and P. F. Lambert. 1995. Bovine papillomavirus type 1 E2 transcriptional regulators directly bind two cellular transcription factors, TFIID and TFIIB. J. Virol. 69:6323-6334.
50. Rush, M., X. Zhao, and S. Schwartz. 2005. A splicing enhancer in the E4 coding region of human papillomavirus type16 is required for early mRNA splicing and polyadenylation as well as inhibition of premature late gene expression. J. Virol. 79:12002-12015.
51. Sakai, H., T. Yasugi, J. D. Benson, J. J. Dowhanick, and P. M. Howley. 1996. Targeted mutagenesis of the human papillomavirus type 16 E2 transactivation domain reveals separable transcriptional activation and DNA replication functions. J. Virol. 70:1602-1611.
52. Sanchez-Perez, A. M., S. Soriano, A. R. Clarke, and K. Gaston. 1997. Disruption of the human papillomavirus type 16 E2 gene protects cervical carcinoma cells from E2F-induced apoptosis. J. Gen. Virol. 78:3009-3018.
53. Sanford, J. R., N. K. Gray, K. Beckman, and J. F. Càceres. 2004. A novel role for shuttling SR proteins in mRNA translation. Genes Dev. 18:755-768.
54. Shih, S.-R., and R. M. Krug. 1996. Novel exploitation of a nuclear function by influenza virus: the cellular SF2/ASF splicing factor controls the amount of the essential viral M2 ion channel protein in infected cells. EMBO J. 15:5411-5427.
55. Sokolowski, M., W. Tan, M. Jellne, and S. Schwartz. 1998. mRNA instability elements in the human papillomavirus type 16 L2 coding region. J. Virol. 72:1504-1515.
56. Somberg, M., X. Zhao, M. Frõhlich, M. Evander, and S. Schwartz. 2008. Polypyrimidine tract binding protein induces human papillomavirus type 16 late gene expression by interfering with splicing inhibitory elements at the major late 5′ splice site, SD3632. J. Virol. 82:3665-3678.
57. Stanley, M. A., H. M. Browne, M. Appelby, and A. C. Minson. 1989. Properties of a non-tumourigenic human cervical keratinocyte cell line. Int. J. Cancer 43:672-676.
58. Steger, G., and S. Corbach. 1997. Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. J. Virol. 71:50-58.
59. WAF1/CIP1 promoter via interaction with Sp1. J. Gen. Virol. 83:503-510.
60. Stoler, M. H., C. R. Rhodes, A. Whitbeck, S. M. Wolinsky, L. T. Chow, and T. R. Broker. 1992. Human papillomavirus type 16 and 18 gene expression in cervical neoplasia. Hum. Pathol. 23:117-128.
61. Stubenrauch, F., A. M. E. Colbert, and L. A. Laimins. 1998. Transactivation by the E2 protein of oncogenic human paillomavirus type 31 is not essential for early and late viral functions. J. Virol. 72:8115-8123.
62. Thierry, F., and P. M. Howley. 1991. Functional analysis of E2-mediated repression of the HPV18 p105 promoter. New Biol. 3:90-100.
63. Webster, K., J. Parish, M. Pandya, P. L. Stern, A. R. Clarke, and K. Gaston. 2000. The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J. Biol. Chem. 275:87-94.
64. Zhao, X., D. Oberg, M. Rush, J. Fay, H. Lambkin, and S. Schwartz. 2005. A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2 and polypyrimidine tract binding protein. J. Virol. 79:4270-4288.
65. Zhao, X., M. Rush, and S. Schwartz. 2004. Identification of an hnRNP A1-dependent splicing silencer in the human papillomavirus type 16 L1 coding region that prevents premature expression of the late L1 gene. J. Virol. 78:10888-10905.
66. zur Hausen, H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2:342-350.